CoLucid Pharmaceuticals (CLCD) IPO Opens Down 15%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
CoLucid Pharmaceuticals Announces Pricing of Initial Public Offering
May 6, 2015 9:00 AM EDTBURLINGTON, Mass., May 6, 2015 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. ("CoLucid") (Nasdaq: CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $10.00 per share.
In addition, CoLucid has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the public offering... More
